With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.
As Curis clinically backs a novel oncology mechanism, several companies might review their own similarly acting projects.
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Loosening of clinical requirements has encouraged more projects into the IgA nephropathy pipeline, with a steroid–based approach from Sweden’s Calliditas looking…